Table 2.
Odds ratios (ORs) for decreasing baseline values of IGFBP-2, adiponectin and IGFBP-1 and increasing baseline values of IGF-I and IGF-II in subjects having normal glucose tolerance (NGT) at baseline in the association to development of prediabetes and type 2 diabetes at follow-up compared to remaining NGT.
| WOMEN | MEN | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NGT | Prediabetes | Type 2 diabetes | NGT | Prediabetes | Type 2 diabetes | ||||||||||
| n | n | OR | 95% CI | n | OR | 95% CI | n | n | OR | 95% CI | n | OR | 95% CI | ||
| IGFBP-2, μg/l | IGFBP-2, μg/l | ||||||||||||||
| >268 | 79 | 14 | 1.00 | 5 | 1.00 | >224 | 92 | 28 | 1.00 | 14 | 1.00 | ||||
| 193-268 | 52 | 34 | 2.70 | 1.25-5.84 | 8 | 0.92 | 0.22-3.87 | 161-224 | 95 | 27 | 0.96 | 0.50-1.83 | 17 | 1.37 | 0.59-3.17 |
| 141-192 | 47 | 32 | 2.15 | 0.97-4.79 | 16 | 2.81 | 0.77-10.26 | 110-160 | 58 | 48 | 2.54 | 1.34-4.82 | 29 | 4.39 | 1.89-10.23 |
| <141 | 22 | 53 | 7.48 | 3.17-17.64 | 26 | 9.52 | 2.59-35.03 | <110 | 32 | 61 | 4.03 | 1.97-8.25 | 38 | 7.63 | 3.13-18.59 |
| continuous, 2log | 200 | 133 | 3.74 | 2.32-6.03 | 55 | 5.31 | 2.43-11.58 | continuous, 2log | 277 | 164 | 2.46 | 1.68-3.60 | 98 | 3.17 | 1.99-5.07 |
| Adiponectin, mg/l | Adiponectin, mg/l | ||||||||||||||
| >15.62 | 74 | 18 | 1.00 | 5 | 1.00 | >10.55 | 84 | 36 | 1.00 | 17 | 1.00 | ||||
| 11.60-15.62 | 62 | 28 | 1.48 | 0.69-3.16 | 5 | 1.19 | 0.25-5.69 | 7.95 - 10.55 | 70 | 41 | 1.17 | 0.64-2.14 | 20 | 1.33 | 0.60-2.91 |
| 8.56-11.59 | 43 | 42 | 2.63 | 1.24-5.57 | 14 | 5.98 | 1.42-25.16 | 6.04 – 7.94 | 74 | 36 | 0.96 | 0.52-1.75 | 27 | 1.56 | 0.73-3.32 |
| <8.56 | 21 | 45 | 6.06 | 2.71-13.57 | 31 | 29.42 | 7.11-121.77 | <6.04 | 49 | 51 | 1.70 | 0.93-3.12 | 34 | 2.35 | 1.11-4.99 |
| continuous, 2log | 200 | 133 | 3.30 | 2.04-5.33 | 55 | 10.89 | 4.41-26.91 | continuous, 2log | 277 | 164 | 1.46 | 1.02-2.10 | 98 | 1.92 | 1.23-2.98 |
| IGFBP-1, μg/l | IGFBP-1, μg/l | ||||||||||||||
| >49 | 73 | 20 | 1.00 | 5 | 1.00 | >35 | 106 | 18 | 1.00 | 9 | 1.00 | ||||
| 35-49 | 63 | 28 | 1.49 | 0.71-3.10 | 8 | 1.60 | 0.42-6.04 | 23 - 35 | 88 | 23 | 1.62 | 0.79-3.31 | 20 | 3.00 | 1.22-7.35 |
| 24-34 | 42 | 39 | 2.83 | 1.35-5.96 | 18 | 4.84 | 1.36-17.19 | 14 - 22 | 57 | 47 | 4.16 | 2.10-8.21 | 29 | 6.33 | 2.56-15.62 |
| <24 | 22 | 46 | 4.27 | 1.86-9.79 | 24 | 5.41 | 1.45-20.12 | <14 | 26 | 76 | 13.44 | 6.33-28.54 | 40 | 14.89 | 5.61-39.48 |
| continuous, 2log | 200 | 133 | 2.17 | 1.47-3.20 | 55 | 2.98 | 1.62-5.48 | continuous, 2log | 277 | 164 | 3.23 | 2.39-4.35 | 98 | 3.19 | 2.20-4.60 |
| IGF-I, μg/l | IGF-I, μg/l | ||||||||||||||
| <150 | 52 | 28 | 1.00 | 18 | 1.00 | <161 | 63 | 42 | 1.00 | 32 | 1.00 | ||||
| 150-182 | 57 | 29 | 0.94 | 0.44-2.01 | 12 | 0.62 | 0.21-1.81 | 161 - 185 | 82 | 36 | 0.60 | 0.32-1.10 | 17 | 0.32 | 0.15-0.68 |
| 183-214 | 53 | 32 | 1.42 | 0.67-2.98 | 12 | 1.14 | 0.38-3.38 | 186 - 218 | 62 | 42 | 1.10 | 0.60-2.04 | 22 | 0.71 | 0.33-1.53 |
| >214 | 38 | 44 | 3.79 | 1.76-8.15 | 13 | 3.37 | 1.04-10.95 | >218 | 70 | 44 | 0.81 | 0.43-1.53 | 27 | 0.70 | 0.33-1.47 |
| continuous, 2log | 200 | 133 | 3.07 | 1.53-6.14 | 55 | 1.56 | 0.58-4.22 | continuous, 2log | 277 | 164 | 1.09 | 0.61-1.95 | 98 | 1.08 | 0.53-2.20 |
| IGF-II, μg/l | IGF-II, μg/l | ||||||||||||||
| <711 | 58 | 25 | 1.00 | 15 | 1.00 | <843 | 80 | 36 | 1.00 | 20 | 1.00 | ||||
| 711-803 | 53 | 32 | 1.70 | 0.81-3.56 | 12 | 0.93 | 0.33-2.63 | 843 - 958 | 77 | 38 | 1.07 | 0.58-1.98 | 21 | 1.06 | 0.49-2.30 |
| 804-929 | 46 | 38 | 2.24 | 1.06-4.72 | 15 | 1.66 | 0.58-4.68 | 959 - 1096 | 58 | 49 | 1.82 | 0.99-3.33 | 26 | 2.11 | 1.00-4.47 |
| >929 | 43 | 38 | 2.39 | 1.13-5.03 | 13 | 0.90 | 0.30-2.68 | >1096 | 62 | 41 | 1.06 | 0.57-1.96 | 31 | 1.80 | 0.86-3.76 |
| continuous, 2log | 200 | 133 | 2.68 | 1.06-6.79 | 55 | 0.71 | 0.18-2.84 | continuous, 2log | 277 | 164 | 1.08 | 0.51-2.26 | 98 | 2.49 | 0.99-6.31 |
Logistic regression models were adjusted for age, BMI (<25.0, 25.0-29.9,≥30.0), physical activity during leisure time (sedentary, moderate, regular exercise), smoking (never, former, current), socioeconomic status (low, middle, high, self-employed) and blood pressure (normal blood pressure and no hypertension treatment vs high blood pressure and/or hypertension treatment).